Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023–2038 (2016).

Article  CAS  PubMed  Google Scholar 

Matthijssen, X. M. E., Niemantsverdriet, E., Huizinga, T. W. J. & van der Helm-van Mil, A. H. M. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands. PLoS Med. 17, e1003296 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).

Article  PubMed  Google Scholar 

Rantapää-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741–2749 (2003).

Article  PubMed  Google Scholar 

van Steenbergen, H. W., Huizinga, T. W. & van der Helm-van Mil, A. H. The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed? Arthritis Rheum. 65, 2219–2232 (2013).

Article  PubMed  Google Scholar 

Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 7, e35296 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chibnik, L. B., Mandl, L. A., Costenbader, K. H., Schur, P. H. & Karlson, E. W. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J. Rheumatol. 36, 706–711 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Woude, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 69, 1554–1561 (2010).

Article  PubMed  Google Scholar 

Bos, W. H., van de Stadt, L. A., Sohrabian, A., Rönnelid, J. & van Schaardenburg, D. Development of anti-citrullinated protein antibody and rheumatoid factor isotypes prior to the onset of rheumatoid arthritis. Arthritis Res. Ther. 16, 405 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Hafkenscheid, L. et al. N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheumatol. 71, 1626–1633 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nielen, M. M. et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50, 2423–2427 (2004).

Article  CAS  PubMed  Google Scholar 

van Steenbergen, H. W., da Silva, J. A. P., Huizinga, T. W. J. & van der Helm-van Mil, A. H. M. Preventing progression from arthralgia to arthritis: targeting the right patients. Nat. Rev. Rheumatol. 14, 32–41 (2018).

Article  PubMed  Google Scholar 

van Nies, J. A. et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann. Rheum. Dis. 73, 861–870 (2014).

Article  PubMed  Google Scholar 

Boers, M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 48, 1771–1774 (2003).

Article  PubMed  Google Scholar 

Quinn, M. A. & Emery, P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin. Exp. Rheumatol. 21, S154–157 (2003).

CAS  PubMed  Google Scholar 

van Nies, J. A., Tsonaka, R., Gaujoux-Viala, C., Fautrel, B. & van der Helm-van Mil, A. H. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann. Rheum. Dis. 74, 806–812 (2015).

Article  PubMed  Google Scholar 

van der Linden, M. P. et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 62, 3537–3546 (2010).

Article  PubMed  Google Scholar 

Burgers, L. E., Raza, K. & van der Helm-van Mil, A. H. Window of opportunity in rheumatoid arthritis — definitions and supporting evidence: from old to new perspectives. RMD Open. 5, e000870 (2019).

Article  PubMed  PubMed Central  Google Scholar 

The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am. J. Med. 98, 156–168 (1995).

Article  Google Scholar 

van der Heide, A. et al. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med. 124, 699–707 (1996).

Article  PubMed  Google Scholar 

van Everdingen, A. A., Jacobs, J. W., Siewertsz Van Reesema, D. R. & Bijlsma, J. W. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med. 136, 1–12 (2002).

Article  PubMed  Google Scholar 

Verstappen, S. M. et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum. 48, 1797–1807 (2003).

Article  PubMed  Google Scholar 

van Dongen, H. et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424–1432 (2007).

Article  PubMed  Google Scholar 

Verstappen, S. M. et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann. Rheum. Dis. 69, 503–509 (2010).

Article  CAS  PubMed  Google Scholar 

Machold, K. P. et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann. Rheum. Dis. 69, 495–502 (2010).

Article  CAS  PubMed  Google Scholar 

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685–699 (2020).

Article  CAS  PubMed  Google Scholar 

Bos, W. H., Dijkmans, B. A., Boers, M., van de Stadt, R. J. & van Schaardenburg, D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann. Rheum. Dis. 69, 571–574 (2010).

Article  CAS  PubMed  Google Scholar 

Gerlag, D. M. et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann. Rheum. Dis. 78, 179–185 (2019).

Article  CAS  PubMed  Google Scholar 

Krijbolder, D. I. et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 400, 283–294 (2022).

Article  PubMed  Google Scholar 

Rech J, K. A. et al. Abatacept delays the development of RA — clinical results after 18 months from the randomized, placebo-controlled ARIAA study in RA-at risk patients [abstract]. Ann. Rheum. Dis. 81, 526 (2022).

Article  Google Scholar 

Deane, K. D. et al. Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial. Arthritis Rheumatol. 74, abstr. 1604 (2022).

Cope, A. et al. Abatacept in individuals at risk of developing rheumatoid arthritis: results from the arthritis prevention in the pre-clinical phase of RA with abatacept (APIPPRA) trial. Ann. Rheum. Dis. 82, 86 (2023).

Google Scholar 

van Boheemen, L. et al. Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open. 7, https://doi.org/10.1136/rmdopen-2021-001591 (2021).

van Steenbergen, H. W. et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann. Rheum. Dis. 76, 491–496 (2017).

Article  PubMed  Google Scholar 

van Steenbergen, H. W., Mangnus, L., Reijnierse, M., Huizinga, T. W. & van der Helm-van Mil, A. H. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann. Rheum. Dis. 75, 1824–1830 (2016).

Article  PubMed  Google Scholar 

Haavardsholm, E. A., Østergaard, M., Ejbjerg, B. J., Kvan, N. P. & Kvien, T. K. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann. Rheum. Dis. 66, 1216–1220 (2007).

Article  PubMed  PubMed Central  Google Scholar 

Østergaard, M. et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann. Rheum. Dis. 64, i3–7 (2005).

Article  PubMed  PubMed Central  Google Scholar 

Mangnus, L., van Steenbergen, H. W., Reijnierse, M. & van der Helm-van Mil, A. H. Magnetic resonance imaging-detected features of inflammation and erosions in symptom-free persons from the general population. Arthritis Rheumatol. 68, 2593–2602 (2016).

Article  CAS  PubMed  Google Scholar 

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3–18 (2023).

Article  CAS  PubMed  Google Scholar 

Wagena